Abiopharma

🔍 Zimmermann Martine (Director)

Company: LIGAND PHARMACEUTICALS INC (LGND)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 836 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,279.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 182 shares of Common Stock at $237.0 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 5,097.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,938 shares of Non-Qualified Stock Option (right to buy) at $237.0 per share (Derivative)
  Date: 2026-06-05 | Code: A | Expires: 2036-06-05 | equity_swap_involved: 0 | shares_owned_after: 2,938.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
• F2: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
• F3: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.